Free Trial
NASDAQ:APGE

Apogee Therapeutics Q3 2023 Earnings Report

Apogee Therapeutics logo
$36.85 -0.84 (-2.22%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Apogee Therapeutics EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Apogee Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apogee Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
6:00AM ET

Upcoming Earnings

Apogee Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Apogee Therapeutics Earnings Headlines

Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
See More Apogee Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email.

About Apogee Therapeutics

Apogee Therapeutics (NASDAQ:APGE), through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

View Apogee Therapeutics Profile

More Earnings Resources from MarketBeat